ENVB is making a statement this morning.


Nasdaq Profile (ENVB) Catches Fire Early, Makes Vertical Move Up Approximately 10% Right Now

Alliance Global Partners $1.25 ENVB Price Target

July 11th

Greetings Readers,

ENVB is making a statement this morning.

Currently up approximately 10% from Friday's close, ENVB was trading at over $.30 during premarket.

Could we see a return to those levels this morning? Here's why there's a chance.

At this moment, ENVB is trading over several lines of potential support including its:

  • 5-Day Simple Moving Average (SMA)
  • 20-Day SMA
  • 50-Day SMA
  • 5-Day Exponential Moving Average (EMA)
  • 13-Day EMA

But taking a look at the chart in the link above, ENVB is still way off from its 200-Day SMA at around $.80.

That could mean there is very little resistance between current levels and that key 200-Day SMA level.

Now, I'm not saying ENVB is going to go soar to that level today, but it's an important level to remember especially when you factor in this profile's $1.25 price target from Alliance Global Partners.

Take a second now and read my initial ENVB report below and get this surging profile on your radar quickly.


There is one specific company trading on the Nasdaq Market that I've been tracking and looks ripe for a potential breakout for several different factors.

And in case you're new to these reports, we've put together a solid few month stretch even when the markets have been getting crushed.

Check them out (all %'s are approximate/short term or intraday):

  • 6/22's profile rocketed 30%
  • 6/7's profile blasted 19%
  • 6/1's profile moved 12%
  • 5/26's profile ran 15%
  • 5/24's profile surged 76%
  • 5/10's profile exploded 194%
  • 5/4's profile shot 38%
  • 5/3's profile blazed 89%

Now, several of those breakout profiles were Nasdaq ideas, but you're probably wondering what makes this one special? Give me a second and I'll get to the meat and potatoes of it.

Imagine for a second that there was a company out there that was doing something that not a single other biotech company was doing by combining two separate explosive markets?

The two markets? Psych-e-delics and Canna-bi-noids.

And just how big are these markets? Take a look for yourself: (2)


Now, even better. What if this company's game-changing, forward-thinking desire to combine these two markets provided them with a chance at a chunk of the $1.27Tn global pharmaceutical industry? (1)

Do I have your complete attention yet? Well, here's one more thing to take into account.

This profile could be gaining steam based on its chart. As of close Friday, it was trading above its:

  • 50-Day Simple Moving Average approx. $.21
  • 13-Day Exponential Moving Average approx. $.21

And with a 200-Day Simple Moving Average of approx. $.80, there could be very little resistance for potential vertical growth near term (upside potential over 200% to 200-Day SMA).

Based on the burgeoning markets this company is looking to disrupt along with a MAJOR analyst price target, a relatively low float, and a recent surge that has created significant potential support levels, there is only one Nasdaq biotech company to have on your screen Monday:


*Enveric Biosciences, Inc. (ENVB)*

Enveric Biosciences is a cutting-edge neuroscience company developing next-generation psych-e-delic-inspired mental health medicines. Enveric's robust pipeline supports dr-ug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD, and more.

And right now, ENVB has multiple potential catalysts that could provide it with a near term breakout spark. Check them out:

No. 1 - Analyst Coverage And $1.25 Price Target

No. 2 - This Proposed Spin-off Could Create Massive Opportunity

No. 3 - A Recent Hot Streak Has ENVB Trading From A Position Of Potential Strength

No. 4 - Low Float Profile/Volatility Potential

But more on those in a second...

Enveric Biosciences Active In Groundbreaking Cancer-Related Clinical Trials

Cancer continues to be the second most common cause of death in the US, after heart disease.

A total of 1.9 million new cancer cases and 609,360 deaths from cancer are expected to occur in the US in 2022, which is about 1,670 deaths a day.(3)

And approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life.(4)

Looking to help solve cancer related distress for millions of patients.

Enveric is working with the University of Calgary’s Hotchkiss Brain Institute (“HBI”) to establish a groundbreaking clinical trial of EVM-101 for the treatment of Cancer Related Distress (“CRD”).(5)

Better still, Enveric is discovering and developing more effective treatments for cancer patients living with psychological distress and is currently working on three classes of new medicines: EVM-101, a first-generation oral psi-lo-cybin; EVM-201, a second-generation pro-dr-ug; and EVM-301, a third-generation psych-e-delic-inspired and optimized new molecule.(5)

More Patents. More Pro-fit Potential To Help Accelerate Innovation

Without the potential for patent profits, there would be no reward for innovative ideas that lead to beneficial products.

Enveric’s next generation molecules are the technological advances that can help make life better.

And these patented molecules can help pharmaceutical companies develop new dr-ugs that can prolong life and provide cures to diseases that affect people worldwide.

On March 15, 2022, Enveric announced that their first four Patent Cooperation Treaty (PCT) applications for the trypt-a-mine family of novel molecules were published by the World Intellectual Property Organization (WIPO).(5)

Trypt-a-mine molecules are being investigated worldwide as potential treatments for a broad range of psychiatric and neurologic disorders, including mood and anxiety disorders, post-traumatic stress disorder, cancer-related distress and more.(5)

With a number of potential catalysts on the horizon, let’s take a closer look at Enveric Biosciences.

Expected Catalysts And Milestones


Enveric Biosciences’ AI-Powered Meds Address The Mind with Psy-che-delics, and the Body with Cann-a-binoids

This is what makes Enveric so incredibly unique with so much potential value. They are perhaps the ONLY publicly traded company that combines both psy-che-delics and cann-a-binoids.

The company sees the big opportunity in psy-che-delics next generation molecules.

They’ve taken the traditional pharma model and made it better by creating end products that work better, with less side effects, that can potentially get to far more patients.

In fact, they are in the process of creating A MASSIVE PROPRIETARY DATABASE of modified molecules which they refer to as the “psybrary.”


In terms of the cann-a-binoid market the big play right now is Radiation Dermatitis (RD). This is one of the most common side effects of cancer radiotherapy, afflicting an incredible 95% of patients receiving radiotherapy.(6)

And the potential market? How about a head-spinning $1Bn opportunity!(6)


Please understand: This tiny $34Mn (approx.) company has filed 14 patents – and potentially has hundreds on the way.


Find more important details in the ENVB company presentation here.


Right now, ENVB has several potential breakout catalysts to know ahead of Monday's opening bell. Here's what to know:

No. 1 ENVB Potential Catalyst - Analyst Coverage And $1.25 Price Target

At the start of June, James Molloy of Alliance Global Partners tagged ENVB with a $1.25 price target.

This gives ENVB over 400% potential upside from its closing valuation as of Friday afternoon.

Here's some highlights from the report:

Valuation: Our 12-18 month price target for ENVB is $1.25/share based primarily on our expectations for EVM-101 for CRD. We model that EVM-101 is approved in 1H28 and launched in 2H28, reaching ~$250M in sales by 2030, year 3 of the launch. We place a 4x multiple on these $250M revenues, discounted back 7 years at 45% for our $0.50/share valuation. We model that EVM-201 is approved in 2H28 and launched in 1H29, reaching ~$350M in sales by 2031, year 3 of the launch. We place a 4x multiple on these $350M revenues, discounted back 8 years at 50% for our $0.45/share valuation. We model that EVM-301 is launched in 2031, reaching ~$750M in sales by 2034, year 3 of the launch. We place a 4x multiple on these $750M revenues, discounted back 11 years at 60% for our $0.15/share valuation. We value the remaining technology at ENVB (primarily the Psybrary machine learning asset for dr-ug discovery) and cash (end-'23E) at $0.15/share for our $1.25/share value at the end of 2023.

Read the full report here.


No. 2 ENVB Potential Catalyst - This Proposed Spin-off Could Create Massive Opportunity

Enveric Biosciences Announces Plans to Spin-off and Dividend its Cann-a-binoid Pipeline to Shareholders

The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psych-e-delic-inspired treatments and the other developing innovative cann-a-binoid treatments

NAPLES, FL, May 11, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psych-e-delic-inspired mental health medicines, today announced plans to transfer and spin-off its cann-a-binoid clinical development pipeline assets to a wholly-owned subsidiary, Acanna Therapeutics Inc. ("Acanna"), by way of dividend to Enveric shareholders. The spin-off transaction will be subject to various conditions, including Acanna meeting the qualifications for listing on The Nasdaq St-ock Market, and if successful, would result in two standalone public companies.

Dr. Joseph Tucker, CEO of Enveric Biosciences, commented, "In these challenging markets, the Board and Management team have spent considerable time evaluating the best way to create additional value for all stakeholders – patients, shareholders, and employees. We believe it would be in the best interest of our shareholders to spin-off 100% equity ownership of our cann-a-binoid clinical development pipeline. Upon completion of the proposed transaction, each resulting public company would be able to focus all its resources on the development of its respective pipeline assets, enabling, we anticipate, greater opportunity for product development success."


Dr. Tucker continued, "For Enveric and Acanna, this spin-off transaction would allow each company to commit 100% of its efforts and capabilities towards developing its respective dr-ug candidate portfolio. For Enveric, going forward, we intend to focus on mental health. We believe that Enveric's achievements in the last year, including preparations for a clinical trial, positive preclinical data, and ongoing expansion of our drug candidate portfolio, the Psybrary™, position us well for the future."

Strategic Rationale for Spinoff

The Company believes that spinning off the cann-a-binoid assets will allow Enveric and Acanna to maximize long-term value for all stakeholders. Following the proposed transaction, both Enveric and Acanna intend to:

  • Have separate, focused management teams with the knowledge and skills to deploy appropriate strategies and meet the unique requirements for each company's operations.
  • Allocate capital more efficiently and strategically to develop their respective assets further.
  • Provide unique in-vest-ment characteristics of interest to the capital markets.

Read the full article here.


No. 3 ENVB Potential Catalyst - A Recent Hot Streak Has ENVB Trading From A Position Of Potential Strength

Over the past two plus weeks, ENVB appears to be heating up.

So much so that (as of 11:00AM EST Friday) it has moved over several lines of potential support.

Those include ENVB's:

  • 5-Day Simple Moving Average (SMA)
  • 20-Day SMA
  • 50-Day SMA
  • 5-Day Exponential Moving Average (EMA)
  • 13-Day EMA

That's great and all, but here's the key detail to pay attention to.

As of 11:00AM EST Friday, ENVB had a 200-Day SMA of just over $.80.

With so much potential support just below ENVB, there may be little resistance towards a return to its 200-Day SMA!

Now, I'm not saying ENVB is going to run 200+% to any previous high around $.80, but you need to be aware of the potential upside from current levels.


No. 4 ENVB Potential Catalyst - Low Float Profile/Volatility Potential

According to the Yahoo Finance website, ENVB has a relatively low float.

The website reports this profile to have approximately 41.61Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.


ENVB Recap - 4 Potential Breakout Catalysts To Know Now

No. 1 - Analyst Coverage And $1.25 Price Target

No. 2 - This Proposed Spin-off Could Create Massive Opportunity

No. 3 - A Recent Hot Streak Has ENVB Trading From A Position Of Potential Strength

No. 4 - Low Float Profile/Volatility Potential


Coverage is officially initiated on ENVB. When time permits, do this:


Get ENVB on your radar now.


Kai Parker


Source 1
Source 2
Source 3
Source 4
Source 5
Source 6

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 7/9/22 and ending on 7/12/22 to publicly disseminate information about (ENVB) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ENVB).